Pitfalls of contrast‐enhanced imaging in the nervous system
- 1 December 1991
- journal article
- review article
- Published by Wiley in Magnetic Resonance in Medicine
- Vol. 22 (2) , 243-248
- https://doi.org/10.1002/mrm.1910220217
Abstract
This brief review covers the evolving clinical role of paramagnetic contrast agents in magnetic resonance imaging of the central nervous system, with particular emphasis on potential pitfalls. The safety and efficacy of Gd‐DTPA is now well‐established. Approximately 35–40% of all scans performed in this country now utilize the agent. The major pitfalls center on overinterpretation of the characterization of disease by either enhancement or lack thereof in any particular process. © 1991 Academic Press, Inc.Keywords
This publication has 11 references indexed in Scilit:
- Normal and abnormal pituitary glands: gadopentetate dimeglumine-enhanced MR imaging.Radiology, 1991
- Magnetic resonance imaging contrast agents: theory and application to the central nervous systemJournal of Neurosurgery, 1990
- Clinical Experience with Routine Gd-DTPA Administration for MR Imaging of the BrainJournal of Computer Assisted Tomography, 1990
- Is Gd-DTPA required for routine cranial MR imaging?Radiology, 1989
- Multiple sclerosis: serial study of gadolinium-enhanced MR imaging.Radiology, 1988
- Increased detection of intracranial metastases with intravenous Gd-DTPA.Radiology, 1987
- Pituitary adenomas in patients with Cushing disease: initial experience with Gd-DTPA-enhanced MR imaging.Radiology, 1987
- Human brain infarcts: Gd-DTPA-enhanced MR imaging.Radiology, 1986
- Multiple sclerosis: gadolinium enhancement in MR imaging.Radiology, 1986
- Acoustic neuromas: Gd-DTPA enhancement in MR imaging.Radiology, 1986